• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Exonate
Novel medicine as a drop to target disease of the eye
Biotech
o2h-ventures

Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.

Transforming the lives of those suffering from vision loss
A revolutionary eye drop
Eye drops to treat diseases such as wet AMD and DME which will not onlyoffer improved quality of life for patients
Status Active
Website https://www.exonate.com/
Category Biotech
Modality Small Molecule
Headquaters Cambridge, UK
Partner Johnson and Johnson
Investment Portfolio Fund Investment
Co-Investors The University Of Nottingham Parkwalk, Angel Cofund, Wren Capital University of Bristol Enterprise Fund

related news

May 13 2017

o2h group update: Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)

ventures

Jul 24 2017

Exonate receives UK Angel Investment Award

ventures

Jan 16 2020

o2h ventures portfolio company Exonate announces collaboration with Johnson & Johnson

ventures

o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
About
  • About Us
  • Team
  • Portfolio
  • Funds
Insights and News
  • Knowledge hub
  • Press releases
  • Blog
  • Event
  • Documents
Connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2024 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)